Therapeutic Effects of Combination Using Glucosamine Plus Tacrolimus (FK-506) on The Development of Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice

Scandinavian Journal of Immunology

Volumn 75, Issue 5, 2012, Pages 471-478

  Kim, C H ^a   Cheong, K A ^b   Park, C D ^c   Lee, A Y ^b  

^a Dongguk University   (South Korea)

^b Dongguk University College of Medicine   (South Korea)

^c Research Institute of Hurim Biocell   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; CYTOKINE; EOTAXIN; GLUCOSAMINE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 5; TACROLIMUS; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATOPHAGOIDES FARINAE; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRY SKIN; EDEMA; EOSINOPHIL; EROSION; ERYTHEMA; HISTOPATHOLOGY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOLOGY; IMMUNOLOGICAL PARAMETERS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LYMPHOCYTE COUNT; MALE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION; SKIN BLEEDING; SKIN DEFECT; T LYMPHOCYTE; TH2 CELL;

ANIMALS; ANTIGENS, CD3; CHEMOKINE CCL11; CHEMOKINE CCL17; CHEMOKINES; CYTOKINES; DERMATITIS, ATOPIC; DERMATOPHAGOIDES FARINAE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; EOSINOPHILS; GLUCOSAMINE; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-13; INTERLEUKIN-5; MALE; MAST CELLS; MICE; SCAVENGER RECEPTORS, CLASS B; SKIN; TACROLIMUS; TH2 CELLS;

EID: 84859405286     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02659.x     Document Type: Article

References (33)

1. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4:1-191.
2. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361:151-60.
3. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004;113:651-7.
4. Wollenberg A, Kraft S, Oppel T, Bieber T. Atopic dermatitis: pathogenetic mechanisms. Clin Exp Dermatol 2000;25:530-4.
5. Grewe M, Bruijnzeel-Koomen CA, Schöpf E. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359-61.
6. Uehara M, Izukura R, Sawai T. Blood eosinophilia in atopic dermatitis. Clin Exp Dermatol 1990;15:264-6.
7. Cooper KD. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 1994;102:128-37.
8. Beltrani VS. Suggestions regarding a more appropriate understanding of atopic dermatitis. Curr Opin Allergy Clin Immunol 2005;5:413-8.
9. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44:S1-12.
10. Sasakawa T, Higashi Y, Sakuma S et al. Atopic dermatitis-like skin lesions induced by topical application of mite antigens in NC/Nga mice. Int Arch Allergy Immunol 2001;126:239-47.
11. Esche C, de Benedetto A, Beck LA. Keratinocytes in atopic dermatitis: inflammatory signals. Curr Allergy Asthma Rep 2004;4:276-84.
12. Towheed TE, Anastassiades T. Glucosamine therapy for osteoarthritis: an update. J Rheumatol 2007;34:1787-90.
13. Reginster JY, Deroisy R, Rovati LC et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
14. Forchhammer L, Thorn M, Met O, Gad M, Weidner MS, Claesson MH. Immunobiological effects of glucosamine in vitro. Scand J Immunol 2003;58:404-11.
15. Ma L, Rudert WA, Harnaha J et al. Immunosuppressive effects of glucosamine. J Biol Chem 2002;277:39343-9.
16. Kim CH, Cheong KA, Park CD, Lee AY. Glucosamine improved atopic dermatitis-like skin lesions in NC/Nga mice by inhibition of Th2 cell development. Scand J Immunol 2011;73:536-45.
17. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007;157:861-73.
18. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999;10:1366-80.
19. Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001;107:519-25.
20. Hiroi J, Sengoku T, Morita K et al. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn J Pharmacol 1998;76:175-83.
21. Sasakawa T, Higashi Y, Sakuma S et al. Topical application of FK506 (tacrolimus) ointment inhibits mite antigen-induced dermatitis by local action in NC/Nga mice. Int Arch Allergy Immunol 2004;133:55-63.
22. Torok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis 2003;72:161-6.
23. Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol 2009;129:31-40.
24. Yamamoto M, Haruna T, Yasui K et al. A novel atopic dermatitis model induced by topical application with dermatophagoides farinae extract in NC/Nga mice. Allergol Int 2007;56:139-48.
25. Suto H, Matsuda H, Mitsuishi K et al. NC/Nga mice: a mouse model for atopic dermatitis. Int Arch Allergy Immunol 1999;120:70-5.
26. Maekawa T, Nojima H, Kuraishi Y, Aisaka K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol 2006;542:179-83.
27. Santamaria-Babi LF. Skin-homing T cells in cutaneous allergic inflammation. Chem Immunol Allergy 2006;91:87-97.
28. Teraki Y, Hotta T, Shiohara T. Increased circulating skin-homing cutaneous lymphocyte-associated antigen (CLA)+ type 2 cytokine-producing cells, and decreased CLA+ type 1 cytokine-producing cells in atopic dermatitis. Br J Dermatol 2000;143:373-8.
29. Van Bever HP. Recent advances in the pathogenesis of atopic dermatitis. Eur J Pediatr 1992;151:870-3.
30. Vestergaard C, Yoneyama H, Murai M et al. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest 1999;104:1097-105.
31. Oshio T, Sasaki Y, Funakoshi-Tago M et al. Dermatophagoides farinae extract induces severe atopic dermatitis in NC/Nga mice, which is effectively suppressed by the administration of tacrolimus ointment. Int Immunopharmacol 2009;9:403-11.
32. Matsuda H, Watanabe N, Geba GP et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997;9:461-6.
33. Lee SY, Shim JY, Kim JH et al. Cyclosporine treatment decreases the percentage of cutaneous lymphocyte antigen (CLA)(+) CD4(+) T cells in children with severe atopic dermatitis. Allergy 2004;59:1129-30.